10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
An oral presentation at the annual meeting of the European Congress of Rheumatology (EULAR) has detailed positive results from a Phase III study of brodalumab (KHK4827). 17 June 2019
Today, at the 24th World Congress of Dermatology (WCD) taking place in Milan, Italy, US biotech firm Incyte (Nasdaq: INCY) presented 24-week data from its Phase II study evaluating ruxolitinib cream as a treatment for adult patients with vitiligo. 15 June 2019
Indian drugmaker Sun Pharmaceutical Industries’ Ilumya is impressing in a new indication beyond its current plaque psoriasis label, new data presented at EULAR has shown. 14 June 2019
Bimekizumab is a crucial pipeline drug for UCB – allowing the company’s to look beyond Cimzia (certolizumab pegol) in immunology – so each successful data read-out is a relief for the Belgian drugmaker. 14 June 2019
Positive topline results from the Phase III PEMPHIX study show Rituxan (rituximab) compares favorably as a therapy for the rare, serious and potentially life-threatening condition pemphigus vulgaris (PV). 14 June 2019
Hutchison China MediTech, also known as Chi-Med, today announced that the independent Data Monitoring Committee (IDMC) of the Phase III pivotal study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic (SANET-ep) has completed a planned interim analysis. 14 June 2019
US pharma major Eli Lilly presented results at EULAR on Friday from the Phase IIIb/IV SPIRIT trial comparing its drug Taltz (ixekizumab) with AbbVie’s Humira (adalimumab) in active psoriatic arthritis (PsA). 13 June 2019
Convincing physicians that their drug is a better option than AbbVie’s Humira has been an aim of a lot of companies at the EULAR congress again this year – with the Chicago-based drugmaker among them. 13 June 2019
UK pharma major GlaxoSmithKline has teamed up with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR), in a five-year collaboration. 13 June 2019
London and New York-listed Mereo BioPharma will regain rights to etigilimab from Celgene, as the American firm elected not to exercise an option on the candidate. 13 June 2019
Privately-held Akrevia Therapeutics today announced that Joseph Farmer has been appointed as chief operating officer of the biopharma company launched by Atlas Ventures and F-Prime last September. 13 June 2019
Shares in CymaBay Therapeutics fell by about 50% on Tuesday, after 12-week top-line results showed the firm’s nonalcoholic steatohepatitis (NASH) candidate seladelpar failed to outperform placebo. 13 June 2019
Singapore-based Tessa Therapeutics, a Temasek-backed clinical stage biotech company, says it will establish a joint venture with China-Singapore Guangzhou Knowledge City (CSGKC). The joint venture will be the sole licensee of Tessa's cell therapies for research, clinical development and commercialization in China. 13 June 2019
Novartis has boasted that Cosentyx (secukinumab) has become the first drug to show efficacy in all key manifestations of psoriatic arthritis (PsA). 12 June 2019
Rare diseases specialist Swedish Orphan Biovitrum saw its shares gain nearly 3% to 175.50 kronor by mid-afternoon, after it revealed plans to take full control of a investigational compound that it had previously only licensed. 12 June 2019
Oncologie, a company that is using proprietary biomarkers to drive development of new drugs for cancer, has closed an $80 Series B financing. 12 June 2019
Swiss oncology-focused drug discovery firm ADC Therapeutics today announced that it has closed a $76 million expansion of its Series E financing, bringing the total gross proceeds raised in the Series E financing to $276 million. 12 June 2019
Texas-based regenerative medicine and cell therapy company InGeneron has raised a further $23 million to advance a pivotal program in rotator cuff tendinopathy, a degenerative and often chronic condition found in a person’s shoulder. 12 June 2019
Denmark’s Novo Nordisk has presented new safety data from the PIONEER 6 trial, testing its landmark oral formulation of the biologic semaglutide, compared with placebo, both in addition to standard of care. 12 June 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024